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Pulmonary arterial hypertension (PAH) when associated with systemic sclerosis 
(SSc) (SSc-PAH) is one of the leading causes of mortality and is found in 
10%–15% of adult patients with SSc. The ET receptor antagonist named 
bosentan has been shown to be effective in the treatment of adult patients with 
SSc-PAH. Furthermore, it has been shown that bosentan ameliorates decreased 
skin perfusion and digital ulceration secondary to SSc. However, the 
effectiveness and safety of bosentan for treatment of juvenile SSc still remains 
unclear. We describe a case of juvenile SSc-PAH successfully treated with 
bosentan. The present case shows that bosentan ameliorated PAH and 
peripheral circulation as evaluated by cold stress thermography. No 
bosentan-related adverse events such as liver dysfunction were observed. 
Prospective randomized trials are required to validate the effectiveness of 
bosentan for patients with juvenile SSc; however, bosentan may be useful for the 
management of patients with juvenile SSc. 
 
Introduction 
Pulmonary arterial hypertension (PAH) when associated with systemic sclerosis 
(SSc) (SSc-PAH) is one of the leading causes of mortality and is found in 
10%–15% of adult patients with SSc [2]. SSc-PAH is less frequent in juvenile 
cases, occurring in only 7.0%–8.7% of cases [4,8]. Plasma endothelin (ET)-1 
levels are increased in patients with SSc, suggesting that ET-1 may be crucial in 
SSc [9]. The ET receptor antagonist named bosentan has been shown to be 
effective in the treatment of adult patients with SSc-PAH [2,7]. Furthermore, it 
has been shown that bosentan ameliorates decreased skin perfusion and digital 
ulceration secondary to SSc [5,6]. A previous report showed that bosentan was 
effective for treatment of children with primary and secondary PAH [3]. However, 
the effectiveness and safety of bosentan for treatment of juvenile SSc still 
remains unclear. Here we describe a case of juvenile SSc-PAH successfully 
treated with bosentan and beraprost. 
 Case report 
A 11-year-old girl had a 1-year history of Raynaud’s phenomenon and skin 
sclerosis of the hands, forearms, legs and face. She visited a local hospital for 
arthralgia of her knees. Physical examination confirmed skin sclerosis of the 
entire body. Furthermore, skin biopsy revealed an increase in thickened collagen 
fibres in the dermis and diagnosis of juvenile SSc was confirmed. Treatment with 
prednisolone was initiated; however, skin sclerosis did not improve, and she 
developed shortness of breath 10 months later. SSc-PAH was suspected and 
she was admitted to our hospital. On admission, her height was 149 cm and 
body weight was 37.8 kg. Physical examination revealed skin sclerosis of the 
entire body with a score of 29 points according to the modified Rodnan total skin 
thickness score (TSS). In addition, diffuse pigmentation on her neck and trunk as 
well as multiple digital pitting scars were observed. Nailfold capillaroscopy 
demonstrated reduced capillary density with dilated and giant capillaries, some 
microhemorrhages and a few avascular areas highly suggestive of SSc. 
High-resolution CT of the lungs did not demonstrate any pathological findings, 
whereas, ventilation/perfusion scans showed negative results. Lung function 
tests revealed a predicted forced vital capacity of 66.8% and a predicted 
diffusing capacity for carbon monoxide of 51.5%. Echocardiography showed a 
tricuspid pressure gradient of 46.1 mmHg and an estimated right ventricular 
systolic pressure of 65 mmHg. Her 6-minute walk distance was 322 m, indicating 
a decreased exercise capacity. Cardiac catheter examination at rest showed a 
mean pulmonary arterial pressure of 41 mmHg, which met the criteria of PAH. 
Serum ET-1 level was significantly increased (2.9 pg/ml; in age matched healthy 
controls; median, 0.9; range, 0.34–1.8).  She was prescribed 62.5 mg/day 
bosentan and 60 μg/day beraprost for PAH and peripheral circulatory 
insufficiency including digital ulceration and Raynaud’s phenomenon. After 1 
week, bosentan was increased to 125 mg/day. After bosentan therapy for 2 
weeks, her estimated right ventricular systolic pressure by echocardiography 
decreased to 38 mmHg. Finally, bosentan was increased to 250 mg/day and 
beraprost to 120 μg/day. In addition to bosentan and beraprost, she was treated 
with six doses of monthly steroid pulse therapy (methylprednisolone 1000 
mg/day, 3 days) and monthly cyclophosphamide pulse therapy 
(cyclophosphamide 500 mg/m2) followed by daily prednisolone (20 mg/day) and 
mizoribine (150 mg/day). After these treatments, her 6-minute walk distance 
increased to 488 m and cardiac catheter examination showed a mean 
pulmonary arterial pressure of 18 mmHg. The decrease in skin temperature of 
the hands also improved (Figure). Furthermore, three doses of steroid and 
cyclophosphamide pulse therapy every 2 months were also added. 
Exacerbation of PAH was absent, and TSS improved to 17 points 1 year after 
initiation of these treatments. No bosentan-related adverse events were 
observed in the patient. 
 Discussion 
ET-1 is a potent mitogenic factor mainly produced by endothelial cells and 
exerts its biological activity by interacting with two cell membrane-bound 
receptors, ET-A and ET-B, expressed on endothelial cells, smooth muscle cells 
and fibroblasts [1]. ET-1 is a potent vasoconstrictor that stimulates synthesis and 
accumulation of extracellular matrix proteins by fibroblasts and smooth muscle 
cells.  
Plasma ET-1 levels are increased in patients with SSc, suggesting that it plays 
a key role in pathogenesis of SSc vascular diseases [9]. Bosentan has been 
shown to be effective for the treatment of patients with SSc-PAH [2,7]. Recently, 
it has been shown that bosentan also ameliorates decreased skin perfusion and 
digital ulceration secondary to SSc [5,6]. These effects may be mediated through 
vasodilatory and antifibrotic effects, indicating that these agents may be 
attractive potential disease modifying agents for SSc. 
However, its effectiveness and safety for patients with juvenile SSc-PAH still 
remains unclear. The present case shows that the combination therapy with 
bosentan and beraprost ameliorated PAH and peripheral circulation as 
evaluated by cold stress thermography. No bosentan-related adverse events 
such as liver dysfunction were observed. Prospective randomized trials are 
required to validate the effectiveness of bosentan for patients with juvenile SSc; 
however, bosentan may be useful for the management of patients with juvenile 
SSc. 
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Figure legend 
Thermal images of the hands 12 min after cold stress. (left, before treatment; 
right, 6 months after the initiation of treatment) 
The dysfunctional cutaneous blood flow in response to cold stimuli was improved 
after bosentan therapy, indicating bosentan ameliorated peripheral circulation. 

